Dogwood Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 41.81M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t...